- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07288203
En studie av Lifileucel (tumorinfiltrerende lymfocytter) hos voksne med avansert melanom
En fase 2, multicentrisk, åpen studie av lifileucel (tumorinfiltrerende lymfocytter [TIL]) hos deltakere med tidligere behandlet avansert melanom
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor
± a MEK inhibitor
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Queensland
-
Greenslopes, Queensland, Australia, 4120
- Greenslopes Private Hospital
-
-
-
-
Ontario, Canada
-
Toronto, Ontario, Canada, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Quebec, Canada
-
Montral, Quebec, Canada, Canada, H2X 0A9
- Centre Hospitalier de l'Universite de Montreal
-
-
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Sarah Cannon Research Institute
-
-
-
-
-
London, Storbritannia, SW3 6JJ
- Royal Marsden Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
- The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
- The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
- Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
- Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
- Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- Participants must have adequate organ function.
- Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion Criteria:
- Participant has melanoma of uveal/ocular origin.
- Participant has symptomatic untreated brain metastases.
- Participant has active uveitis that requires active treatment.
- Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
- Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
- Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
- Participant has a history of allogeneic cell or organ transplant.
- Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Other protocol defined inclusion/exclusion criteria could apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single Arm
Lifileucel |
A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate
Tidsramme: 12 months
|
To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators |
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Response Rate
Tidsramme: 12 months
|
To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Duration of Response
Tidsramme: 12 months
|
To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Disease Control Rate
Tidsramme: 12 months
|
To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Progression-Free Survival
Tidsramme: 12 months
|
To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators |
12 months
|
|
Overall Survival
Tidsramme: 18 months
|
To evaluate the efficacy of lifileucel as measured by OS |
18 months
|
|
Adverse Events
Tidsramme: 18 months
|
To demonstrate safety and tolerability of lifileucel |
18 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IOV-MEL-202
- 2025-522054-40-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .